A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors
Stopped The study was terminated due to marginal efficacy and change in sponsor prioritization. The combination had a manageable safety profile.
Conditions
- Advanced/Metastatic Solid Tumors
Interventions
- DRUG: PF-05082566
- DRUG: KW-0761
Sponsor
Pfizer
Collaborators